Active Ingredient: Given medicine is a combination of two active ingredients. Dipyridamole is a synthetic agent derivative of pyrimido-pyrimidine, with antiplatelet properties. It inhibits adenosine uptake by platelets and endothelial cells, triggering an accumulation of cyclic adenosine monophosphate. It inhibits the stimulation of platelet aggregation by agents such as platelet activating factor and collagen.
Aspirin is a non-steroidal antiinflammatory agent that binds to and acetylates serine residues in cyclooxygenases, resulting in decreased synthesis of prostaglandin, platelet aggregation, and inflammation.
Indications: Given medication is approved to reduce the risk of stroke in patients who have had “mini-strokes” or a previous stroke due to a blood clot and are at high risk for another stroke. This medicine composed of two components. It works to keep blood flowing to the brain by stopping platelets from clumping together. Aggrenox prevents the platelets from forming blood clots, which can lodge in the brain and cause a certain type of stroke (ischemic stroke).
Action Mechanism: This medicine a combination of is an aspirin/extended-release dipyridamole combination that acts on multiple mechanisms of the platelet-aggregation process to prevent clumping and clotting.
Dosages: This medication Aggrenox is available for oral consumption and in dosage as mentioned below:
- 200 mg + 25 mg: It is an oral drug shall be taken with or without food as directed by the doctor, usually twice a day
Note: You should not take this medicine if you have asthma and also have polyps in your nose.